- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
However, the most common type of b cell lymphoma is diffuse large b-cell lymphoma (DLBCL), and researchers have come up with a rather handy method of determining prognosis for people with DLBCL. The method is known by its initials, the R-IPI, which stands for the Revised International Prognostic Index.
The R-IPI works by identifying a specific patient group—those who have been diagnosed with DLBCL and who are then treated with the R-CHOP chemotherapeutic regimen.
[*ECOG status: This is a scale to determine how a disease affects a patient's daily life. To see what each score means, refer to this explanation offered by the National Cancer Institute. ]
The R-IPI doesn't recognize risk groups with a perceived B cell lymphoma survival rate of under 50%.
Researchers are always looking for new methods to determine survival rates, especially among b cell lymphomas, because they are so common, but readers should be aware of the limitations of these indices since each person is different and each person's cancer is also different.